Company
(Symbol)

Product

Description

Indication

Status (Date)

CANCER

Atrix Labora-
tories Inc.
(ATRX) and
MediGene AG
(Germany; Neuer
Markt:MDG)

Leuprogel One-Month Depot

Leuprolide acetate

Prostate cancer

Companies submitted a market authorization application in Germany (12/4)

Ligand Pharma-
ceuticals Inc.
(LGND)

Onzar

Denileukin diftitox

Cutaneous T-cell lymphoma

Company submitted a regulatory application to market Onzar in Europe (12/19)

Novogen
Ltd. (Australia;
NVGN)

Phenoxodiol

Small molecular signal transduction inhibitor designed to target abnormal signaling processes in cells

Leukemia

Company began a Phase Ib/IIa trial in Australia (12/18)

Orphan
Medical
Inc. (ORPH)

Busulfex
(FDA-
approved)

Busulfan

Leukemia, lymphoma and myelodysplastic syndrome

Company gained approval of Busulfex in South Korea in combination with cyclophosphamide to treat certain leukemias, lymphoma and myelodysplastic syndrome (12/3)

Valentis Inc.
(VLTS) and
Roche Hold-
ings Ltd.

IL-2 Gene-
Medicine

Plasmid encoding the human interleukin-2 gene and a cationic lipid gene-delivery system

Head and neck cancer

Phase IIb test results were poor showing the product didn't work at the tested dose in this indication; the trial was conducted in Germany, the Czech Republic and Russia (12/3)

CARDIOVASCULAR

Actelion Ltd.
(Switzerland;
SWX:ATLN)

Tracleer

Bosentan tablets

Pulmonary arterial hypertension

The Canadian Health Authority approved Tracleer (12/3)

GlycoDesign
Inc. (Canada;
TSE:GD) and Leo Pharmaceutical Products Ltd. (Denmark)

GH9001

Antithrombotic drug candidate

Thrombosis

Companies initiated a Phase I trial in the UK (12/20)

Transkaryotic
Therapies Inc.
(TKTX)

Dynepo

Epoetin delta; human erythropoietin

Anemia associated with renal disease

A European evaluation committee issued a positive opinion recommending approval (12/12)

INFECTION

Cangene Corp.
(Canada; TSE:
CNJ)

Anti-hepatitis B hyperimmune

Hepatitis B

Company filed a new drug submission in Canada (12/18)

MISCELLANEOUS

Paladin Labs
Inc. (Canada; TSE: PLB) and Orphan Medical Inc. (ORPH)

Antizol

Fomepizole injection

Methanol poisoning

Antizol was approved in Canada (12/5)

Transgene SA
(France; TRGNY)

MVA-
HPV-IL2

Vaccine

Vulvar intraepithelial neoplasia

Company initiated a Phase II trial in France (12/18)

Notes:

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

TSE = Toronto Stock Exchange; SWX = Swiss Stock Exchange